ZIVO RSI Chart
Last 7 days
-0.9%
Last 30 days
-2.1%
Last 90 days
-5.1%
Trailing 12 Months
152.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 63.4K | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 27.6K |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 0 |
2019 | 1.8M | 2.3M | 2.4M | 2.0M |
2018 | 2.0M | 2.1M | 1.4M | 2.0M |
2017 | 2.0M | 1.0M | 1.9M | 1.8M |
2016 | 1.3M | 1.5M | 1.7M | 1.9M |
2015 | 0 | 0 | 0 | 1.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 02, 2024 | cornell alison a | bought | 49,999 | 1.2 | 41,666 | - |
Dec 29, 2023 | maggiore christopher d. | bought | 205,000 | 1.3 | 157,692 | - |
Dec 13, 2023 | maggiore christopher d. | bought | 45,000 | 1.00 | 45,000 | - |
Dec 19, 2022 | masterson nola e | bought | 792 | 2.64 | 300 | - |
Dec 19, 2022 | payne john bernard | bought | 142 | 2.5 | 57.00 | president and ceo |
Dec 13, 2022 | cornell alison a | bought | 36,000 | 3.00 | 12,000 | - |
Sep 14, 2022 | maggiore christopher d. | bought | 25,447 | 3.53438 | 7,200 | - |
Feb 11, 2022 | maggiore christopher d. | bought | 173,952 | 3.8686 | 44,965 | - |
Feb 10, 2022 | maggiore christopher d. | bought | 65,451 | 3.635 | 18,006 | - |
Which funds bought or sold ZIVO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 09, 2024 | BARTLETT & CO. WEALTH MANAGEMENT LLC | sold off | -100 | -216 | - | -% |
Jan 08, 2024 | Bartlett & Co. LLC | new | - | - | - | -% |
Jan 08, 2024 | Bartlett & Co. LLC | sold off | -100 | -1,000 | - | -% |
Nov 13, 2023 | Ayrton Capital LLC | unchanged | - | -7,420,000 | 21,885,000 | 0.15% |
Nov 03, 2023 | Column Capital Advisors, LLC | unchanged | - | -13,440 | 15,600 | -% |
Unveiling Zivo Bioscience, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Zivo Bioscience, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Zivo Bioscience, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | 202.7% | 36.00 | 12.00 | 12.00 | 4.00 | 266 | 527 | 321 | 164 | 888 | 1,611 | 219 | 244 | 270 | 709 | 720 | 292 | 662 | 623 | 254 | 424 | 117 |
Gross Profit | 202.6% | 13.00 | 4.00 | 4.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | - | - | - | - | - | - | 1,706 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | -32.2% | 1,288 | 1,901 | 1,577 | 1,827 | 1,970 | 1,673 | 1,749 | 2,084 | 1,755 | 3,365 | 1,030 | 2,426 | 3,773 | 1,574 | 2,037 | 968 | 1,617 | 1,495 | 1,335 | - | - |
S&GA Expenses | -100.0% | - | 1,588 | 1,356 | 1,385 | 1,568 | 1,264 | 1,281 | 1,437 | 3,294 | 459 | 374 | 694 | 3,036 | 340 | 370 | 309 | 397 | 317 | 307 | 332 | - |
R&D Expenses | 0.1% | 313 | 312 | 221 | 442 | 402 | 409 | 468 | 647 | 447 | 1,295 | 437 | 1,576 | 467 | 526 | 948 | 366 | 559 | 555 | 774 | - | - |
Interest Expenses | 106.1% | 3.00 | -43.70 | 33.00 | 32.00 | 3.00 | 209* | 19.00 | 24.00 | 37.00 | 24.00 | 24.00 | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 33.0% | -1,278 | -1,908 | -1,824 | -2,070 | -1,973 | -1,551 | -1,845 | -2,218 | -1,893 | -3,502 | -1,166 | -2,542 | -4,131 | -1,781 | -2,540 | -3,057 | -3,097 | -4,118 | -3,573 | - | - |
Net Income Margin | 60.3% | -111.76* | -281.27* | -4.27* | -4.36* | -4.37* | -3.77* | -4.75* | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -137.4% | -1,699 | -715 | -1,969 | -985 | -2,128 | -1,801 | -2,048 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 46.9% | 816 | 556 | 2,102 | 710 | 1,128 | 2,123 | 3,971 | 5,865 | 7,688 | 8,990 | 10,972 | 11,104 | 649 | 390 | 130 | 223 | 179 | 369 | 70.00 | 112 | 104 |
Current Assets | 67.1% | 711 | 425 | 1,948 | 530 | 928 | 1,902 | 3,729 | 5,601 | 7,454 | 8,960 | 10,935 | 11,062 | 458 | 168 | 130 | 223 | 179 | 369 | 70.00 | 112 | 104 |
Cash Equivalents | -100.0% | - | 274 | 1,485 | 21.00 | 209 | 1,799 | 3,386 | 5,084 | 6,599 | 8,902 | 10,803 | 10,903 | 232 | 138 | 55.00 | 119 | 10.00 | 346 | 15.00 | 44.00 | 4.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 11.7% | 3,085 | 2,762 | 3,196 | 3,855 | 2,870 | 2,134 | 2,447 | 2,854 | 3,104 | 2,948 | 3,201 | 3,771 | 12,073 | 11,531 | 11,221 | 10,216 | 9,327 | 8,708 | 10,973 | 11,271 | 24,803 |
Current Liabilities | 11.7% | 3,085 | 2,762 | 3,174 | 3,804 | 2,791 | 2,028 | 2,315 | 2,697 | 2,959 | 2,948 | 3,198 | 3,642 | 11,941 | 11,394 | 11,100 | 10,094 | 9,327 | 8,708 | 10,973 | 11,271 | 24,803 |
Shareholder's Equity | -2.9% | -2,268 | -2,205 | - | - | -1,741 | -10.62 | 1,524 | 3,010 | 4,585 | 6,042 | 7,771 | 7,333 | - | - | - | - | - | - | - | - | - |
Retained Earnings | -1.0% | -124,860 | -123,581 | -121,673 | -119,848 | -117,777 | -115,804 | -113,163 | -112,327 | -110,255 | -107,059 | -104,712 | -103,128 | -101,282 | -99,063 | -97,170 | -93,667 | -92,500 | -89,957 | -85,826 | -84,044 | -81,504 |
Additional Paid-In Capital | 1.0% | 122,589 | 121,373 | 120,577 | 116,694 | 116,027 | 115,792 | 114,679 | 115,328 | 114,830 | 113,092 | 112,474 | 110,452 | 89,438 | 87,748 | 85,673 | 83,268 | 82,949 | 81,223 | 74,565 | 72,544 | 56,619 |
Shares Outstanding | 17.1% | 2,790 | 2,382 | 1,742 | 1,570 | 1,570 | 1,570 | 1,570 | 1,570 | 1,570 | 1,570 | 1,570 | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 17,300 | - | - | - | 28,300 | - | - | - | 29,200 | - | - | - | 27,358 | - | - | - | 18,826 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -137.4% | -1,699 | -715 | -1,969 | -985 | -2,128 | -1,447 | -1,488 | -1,305 | -2,861 | -1,901 | -1,801 | -2,048 | -1,052 | -901 | -564 | -339 | -783 | -651 | -1,326 | -1,153 | -576 |
Share Based Compensation | - | - | - | - | - | - | - | - | - | 571 | - | - | - | 975 | - | - | - | - | - | - | - | - |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | 416.1% | 1,563 | -494 | 3,433 | 798 | 538 | -139 | -209 | -209 | 559 | 1* | 1,702 | 12,720 | 1,146 | 984 | 501 | 449 | 447 | 982 | 1,298 | 1,193 | 192 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
REVENUES: | ||
Product revenue | $ 35,720 | $ 0 |
Total revenues | 35,720 | 0 |
COSTS OF GOODS SOLD | ||
Product costs | 23,218 | 0 |
Total costs of goods sold | 23,218 | 0 |
GROSS MARGIN | 12,502 | 0 |
COSTS AND EXPENSES: | ||
General and administrative | 975,574 | 1,568,377 |
Research and development | 312,767 | 401,797 |
Total costs and expenses | 1,288,341 | 1,970,174 |
LOSS FROM OPERATIONS | (1,275,839) | (1,970,174) |
OTHER (EXPENSE): | ||
Interest expense | (2,648) | (2,968) |
Total other expense | (2,648) | (2,968) |
NET LOSS | $ (1,278,486) | $ (1,973,142) |
BASIC AND DILUTED LOSS PER SHARE | $ (0.47) | $ (1.26) |
WEIGHTED AVERAGE BASIC AND DILUTED SHARES OUTSTANDING | 2,748,294 | 1,569,943 |
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS: | ||
Cash | $ 138,641 | $ 274,380 |
Accounts receivable | 3,735 | 3,735 |
Prepaid expenses | 568,241 | 147,262 |
Total current assets | 710,617 | 425,377 |
OTHER ASSETS: | ||
Operating lease - right of use asset | 73,721 | 98,280 |
Security deposit | 32,058 | 32,058 |
Total other assets | 105,779 | 130,338 |
TOTAL ASSETS | 816,396 | 555,715 |
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT): | ||
Accounts payable | 705,841 | 993,090 |
Accounts payable - related party | 211,170 | 172,670 |
Current portion of long-term operating lease | 79,033 | 106,342 |
Convertible debentures payable | 240,000 | 240,000 |
Loan Payable | 460,053 | 0 |
Accrued interest | 101,278 | 100,686 |
Accrued liabilities - employee bonus | 1,287,920 | 1,148,770 |
Total current liabilities | 3,085,295 | 2,761,558 |
LONG TERM LIABILITIES: | 0 | 0 |
TOTAL LIABILITIES | 3,085,295 | 2,761,558 |
STOCKHOLDERS' EQUITY (DEFICIT): | ||
Common stock, $0.001 par value, 25,000,000 and 25,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 2,789,655 and 2,382,356 issued and outstanding at March 31, 2024, and December 31, 2023, respectively | 2,791 | 2,383 |
Additional paid-in capital | 122,588,510 | 121,373,488 |
Accumulated deficit | (124,860,200) | (123,581,714) |
Total stockholders' equity (deficit) | (2,268,899) | (2,205,843) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 816,396 | $ 555,715 |